Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer

International Immunopharmacology

Volumn 8, Issue 5, 2008, Pages 717-724

  Habjanec, Lidija ^a   Halassy, Beata ^a   Tomašić, Jelka ^a  

^a INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

Montanide ISA206; Montanide ISA720; Peptidoglycan monomer; Th1 Th2

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MONTANIDE ISA206; MONTANIDE ISA720; OVALBUMIN; PEPTIDOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG FORMULATION; FEMALE; IMMUNOMODULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREUND'S ADJUVANT; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-4; LYMPH NODES; MANNITOL; MICE; MICE, INBRED CBA; OLEIC ACIDS; OVALBUMIN; PEPTIDOGLYCAN; TH1 CELLS; TH2 CELLS;

EID: 41349084148     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.01.017     Document Type: Article

References (33)

1. Aucouturier J., Ascarateil S., and Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 24 (2006) S44-S45
2. Cox S.J., Aggarwal N., Statham R.J., and Barnett P.V. Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines. Vaccine 21 (2003) 1336-1347
3. Halassy B., Vdović V., Habjanec L., Lang Balija M., Gebauer B., Sabioncello A., et al. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits. Vaccine 25 (2007) 3475-3481
4. Keglević D., Ladešić B., Hadžija O., Tomašić J., Valinger Z., Pokorny M., et al. Isolation and study of the composition of a peptidoglycan complex excreted by the biotin-requiring mutant of Brevibacterium divaricatum NRRL-2311 in the presence of penicillin. Eur J Biochem 42 (1974) 389-400
5. Keglević D., Ladešić B., Tomašić J., Valinger Z., and Naumski R. Isolation procedure and properties of monomer unit from lysozyme digest of peptidoglycan complex excreted into the medium by penicillin-treated Brevibacterium divaricatum mutant. Biochim Biophys Acta 585 (1979) 273-281
6. Tomašić J., Hanzl-Dujmović I., Špoljar B., Vranešić B., Šantak M., and Jovičić A. Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse. Vaccine 18 (2000) 1236-1243
7. Halassy Špoljar B., Čimbora T., Hanzl-Dujmović I., Dojnović B., Sabioncello A., Krstanović M., et al. Influence of adjuvant-active peptidoglycan monomer on specific T cell responses in mice. Vaccine 20 (2002) 3543-3550
8. Halassy B., Mateljak S., Bouche F.B., Pütz M.M., Muller C.P., Frkanec R., et al. Immunogenicity of peptides of measles virus origin and influence of adjuvants. Vaccine 24 (2006) 85-94
9. Lang Balija M. Immune reaction specific for venom of long-nosed viper (Vipera ammodytes) in mice and influence of adjuvants. Master of Science Thesis. Zagreb, 2002. (in Croatian).
10. 14C-labelled peptidoglycan monomer in mice. Identification of the monomer and the corresponding pentapeptide in urine. Biochim Biophys Acta 629 (1980) 77-82
11. Valinger Z., Ladešić B., and Tomašić J. Partial purification of N-acetylmuramyl-l-alanine amidase from human and mouse serum. Biochim Biophys Acta 701 (1982) 63-71
12. Krstanović M., Brgles M., Halassy B., Frkanec R., Vrdoljak A., Branović K., et al. Purification and characterization of l,(l/d)-aminopeptidase from guinea pig serum. Prep Biochem Biotechnol 6 (2006) 175-195
13. Halassy B., Krstanović M., Frkanec R., and Tomašić J. Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine 21 (2003) 971-976
14. Habjanec L, Halassy B, Vdović V, Lang Balija M, Tomašić J. Comparison of mouse and rabbit model for the assesment of strong PGM-containing oil-based adjuvants. Vet Immunol Immunopathol. doi:10.1016/j.vetimm.2007.09.014.
15. Chang J.C.C., Diveley J.P., Savary J.R., and Jensen F.C. Adjuvant activity of incomplete Freund's adjuvant. Adv Drug Deliv Rev 32 (1998) 173-186
16. Stewart-Tull DES. The assessment and use of adjuvants. In: Gregoriadis, et al. (Ed). Vaccines (1991), Plenum Press, New York 85-92
17. Krstanović M., Frkanec R., Vranešić B., Ljevaković D{stroke}., Šporec V., and Tomašić J. Reversed-phase high-performance liquid chromatographic method for the determination of peptidoglycan monomers and structurally related peptides and adamantyltripeptides. J Chromatogr B 773 (2002) 167-174
18. Habjanec L., Frkanec R., Halassy B., and Tomašić J. Effect of liposomal formulations and immunostimulating peptidoglycan monomer (PGM) on the immune reaction to ovalbumin in mice. J Liposome Res 16 (2006) 1-16
19. Wright S.P. Adjusted P-values for simultaneous inference. Biometrics 27 (1992) 77-81
20. Stewart-Tull DES. Recommendations for the assessment of adjuvants (immunopotentiators). In: Gregoriadis G., Allison A.C., and Poste G. (Eds). Immunological adjuvants and vaccines (1991), Plenum Publishing Corporation, New York 213-226
21. Edelman R. An overview of adjuvant use. In: O'Hagan D.T. (Ed). Vaccine adjuvants: Preparation Methods and Research Protocols. Methods in Molecular Medicine vol. 42 (2000), Humana Press, Inc., Totowa, New Jersey 1-27
22. Sachdeva S., Ahmad G., Malhotra P., Mukherjee P., and Chauhan V.S. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kilodalton fragments expressed in Escherichia coli. Infect Immun 72 (2004) 5775-5782
23. Sachdeva S., Mohmmed A., Dasaradhi P.V.N., Crabb B.S., Katyal A., Malhotra P., et al. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-142 using human compatible adjuvants. Vaccine 24 (2006) 2007-2016
24. Dutta S., Ware L.A., Barbosa A., Ockenhouse C.F., and Lanar D.E. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli. Infect Immun 69 (2001) 5464-5470
25. Yazdani S.S., Shakri A.R., Mukherjee P., Baniwal S.K., and Chitnis C.E. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 22 (2004) 3727-3737
26. Leenars P.P.A.M., Hendriksen C.F.M., de Leeuw W.A., Carat F., Delahaut P., Fischer R., et al. The production of polyclonal antibodies in laboratory animals. ATLA 27 (1999) 79-102
27. http://www.harlan.com.
28. Johansson J., Ledin A., Vernersson M., Lövgren-Bengtsson K., and Hellman L. Identification of adjuvants that enhance the therapeutic antibody response to host IgE. Vaccine 22 (2004) 2873-2880
29. Hirunpetcharat C., Wipasa J., Sakkhachornphop S., Nitkumhan T., Zheng Y.Z., Pichyangkul S., et al. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine 21 (2003) 2923-2932
30. Roohvand F., Aghasadeghi M.R., Sadat S.M., Budkowska A., and Khabiri A.R. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun 354 (2007) 641-649
31. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvant, enhance the magnitude and change the bias of the immune response to a herpesvirus glycoprotein. Vaccine 21 (2002) 127-137
32. Jin B., Wang R.Y., Qiu Q., Sugauchi F., Grandinetti T., Alter H.J., et al. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology 122 1 (2007) 15-27
33. Jeamwattanalert P., Mahakunkijcharoen Y., Kittigul l., Mahannop P., Pichyangkul S., and Hirunpetcharat C. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Clin Vaccine Immunol 14 4 (2007) 342-347